Imaging software developer Syntermed has received U.S. Food and Drug Administration (FDA) 510(k) clearance for version 3.6 of its NeuroQ nuclear medicine software.
The latest version of NeuroQ, which is used in nuclear medicine clinics for PET brain scans, now has clearance for the analysis of amyloid uptake levels in various brain regions, according to the vendor. The software will analyze the distribution of FDG and amyloid PET tracers in individual scans, as well as the difference between two PET scans on the same patient taken at different times.
The software then automatically calculates values within predefined regions of the brain to assist with final interpretation of the images, Syntermed said.
